Haemonetics Corporation

US$119.93As of Sun 8 Nov 2026, 12:00 UTC
NYSE:HAEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 13.60%
Div yield —
ROE 11.89%
Medical Devices
Beta (5Y) 0.59
PE TTM 53.58
TSR TTM 139.81%
Mkt cap US$5.461B
ROIC 10.75%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$143
19.33%
140.53%
Hold 10|6|6|2|5
3Q26
4Q26
1Q27
2Q27
Earnings per share$
2.18
2.41
2.47
2.69
(7.86%)
6.07%
8.79%
24.04%
Revenue$M
368.8
379.7
373.0
365.9
4.22%
4.77%
2.15%
2.72%
Peers (US$5.461B)
Cap (US$)
PE
9.363B
—
7.797B
—
4.303B
42.26x
5.954B
39.33x
Capital
TTM
5Y
10Y
Leveragex
0.384
0.026
0.027
EBIT/Intx
6.885
0.174
0.174
Own earn%
(142.51)
(0.77)
0.96
Sh yield%
35.24
29.87
28.82
Owners
Insiders/Inst%
8.66
29.58
Short interest%
5.43
SBC / revenue%
3.57
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
14–20
$1 testx
—
Incr. ROIC%
4